NCT03694262 2026-04-13
EndoBARR
Medical College of Wisconsin
Phase 2 Completed
Clinical Trials
15 trialsNCT02873962 2026-04-01
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03617679 2026-03-24
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
University of Colorado, Denver
Phase 2 Completed
NCT04539327 2026-03-18
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
Grupo Español de Investigación en Cáncer de Ovario
Completed
NCT03559049 2026-02-12
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT03542175 2025-12-08
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03639935 2025-06-03
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03958045 2024-10-22
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
University of Kentucky
Phase 2 Completed
NCT03413995 2024-10-16
TRIUMPH
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01074970 2024-09-19
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Hoosier Cancer Research Network
Phase 2 Completed
NCT03337087 2024-05-17
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Academic and Community Cancer Research United
Phase 1/2 Active not recruiting
NCT03533946 2024-03-13
ROAR
University of Utah
Phase 2 Terminated
NCT03476798 2024-02-15
Clovis-001
University of Oklahoma
Phase 2 Completed
NCT03140670 2023-09-28
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT03572478 2021-03-09
Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
University of Chicago
Phase 1/2 Terminated